The significance of autologous hematopoietic stem cell transplantation on immunoglobulin reconstitution and prognosis in elderly patients with multiple myeloma

References

• Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017 Aug;33(3):225–236. doi:10.1016/j.soncn.2017.05.012
   PubMed Web of Science ®Google Scholar
• Mikulski D, Robak P, Perdas E, et al. Pretreatment serum levels of IL-1 receptor antagonist and IL-4 are predictors of overall survival in multiple myeloma patients treated with bortezomib. J Clin Med. 2021 Dec 26;11(1). doi:10.3390/jcm11010112
   PubMed Web of Science ®Google Scholar
• Tagliafico AS, Dominietto A, Belgioia L, et al. Quantitative imaging and radiomics in multiple myeloma: a potential opportunity? Medicina (Kaunas, Lithuania). 2021 Jan 21;57(2):94), doi:10.3390/medicina57020094.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Peng H. The role of N(6)-methyladenosine (m(6)A) methylation modifications in hematological malignancies. Cancers. 2022 Jan 11;14(2). doi:10.3390/cancers14020332
   Web of Science ®Google Scholar
• Rinaldi I, Muthalib A, Edina BC, et al. Role of anti-B-cell maturation antigen (BCMA) in the management of multiple myeloma. Cancers. 2022 Jul 19;14(14). doi:10.3390/cancers14143507
   Web of Science ®Google Scholar
• Rafae A, Malik MN, Abu Zar M, et al. An overview of light chain multiple myeloma: clinical characteristics and rarities, management strategies, and disease monitoring. Cureus. 2018 Aug 15;10(8):e3148.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019 Jun;37 Suppl 1(Suppl 1):62–65. doi:10.1002/hon.2586
   PubMedGoogle Scholar
• Xiang RF, Wang Y, Zhang N, et al. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017 May 11;8(5):e2776. doi:10.1038/cddis.2017.188
   PubMedGoogle Scholar
• Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation. Curr Oncol. 2019 Jun;26(3):187–191. doi:10.3747/co.26.5033
   PubMed Web of Science ®Google Scholar
• Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019 Apr 8;9(4):44. doi:10.1038/s41408-019-0205-9
   PubMedGoogle Scholar
• Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022 May;97(Suppl 1):S3–s25.
   PubMedGoogle Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订). 中华内科杂志 2020年59卷5期 341–346页 MEDLINE ISTIC PKU CSCD CA. 2021.
   Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009 Jan;23(1):3–9. doi:10.1038/leu.2008.291
   PubMed Web of Science ®Google Scholar
• Gao F, Lin MS, You JS, et al. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int. 2021 Nov 10;21(1):601. doi:10.1186/s12935-021-02313-z
   PubMed Web of Science ®Google Scholar
• Cho HJ, Jung SH, Jo JC, et al. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT. Blood Cancer J. 2021 Dec 1;11(12):190. doi:10.1038/s41408-021-00577-2
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson SY, et al. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010 Mar;85(3):225–230. doi:10.4065/mcp.2009.0426
   PubMed Web of Science ®Google Scholar
• Sanchez L, Sylvester M, Parrondo R, et al. In-Hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: A population-based study. Biol Blood Marrow Tr: J Am Soc Blood Marrow Tr. 2017 Jul;23(7):1203–1207. doi:10.1016/j.bbmt.2017.03.012
   PubMed Web of Science ®Google Scholar
• González-Barrera S, Martín-Sánchez G, Parra-Jordán JJ, et al. Feasibility of a hospital-at-home program for autologous hematopoietic stem cell transplantation. Transplant Cell Ther. 2023 Feb;29(2):111.e1–111.e7. doi:10.1016/j.jtct.2022.11.018
   PubMedGoogle Scholar
• Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016 Jan;91(1):101–119. doi:10.1016/j.mayocp.2015.11.007
   PubMed Web of Science ®Google Scholar
• Lu J, Ding J, Liu Z, et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). Int J Oncol. 2022 Feb;60(2).
   Web of Science ®Google Scholar
• Duan Z, Baughn LB, Wang X, et al. Role of Dot1L and H3K79 methylation in regulating somatic hypermutation of immunoglobulin genes. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2104013118.doi:10.1073/pnas.2104013118.
   PubMed Web of Science ®Google Scholar
• Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immun (Orlando, Fla). 2018 Jun;191:110–115. doi:10.1016/j.clim.2017.11.014
   PubMed Web of Science ®Google Scholar
• Amjad MA, Hamid Z, Ramakrishna S, et al. Myelomatous pleural effusion: a rare occurrence in multiple myeloma. Cureus. 2022 Jun;14(6):e26045.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zagouri F, Symeonidis A, et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014 Oct;28(10):2075–2079. doi:10.1038/leu.2014.110
   PubMed Web of Science ®Google Scholar
• Harutyunyan NM, Vardanyan S, Ghermezi M, et al. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol. 2016 Jul;174(1):81–87. doi:10.1111/bjh.14026
   PubMed Web of Science ®Google Scholar